Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China

INTRODUCTION: The survival of patients with relapsed small cell lung cancer (SCLC) has achieved little progress in the last several decades. ALTER1202 confirmed the efficacy and safety of anlotinib as a third- or further-line option for relapsed SCLC. This study aimed to assess the cost-effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jinhong, Wan, Qian, Shang, Jingjing, Qian, Xiaodan, Su, Dan, Sun, Zhiqiang, Liu, Guangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379562/
https://www.ncbi.nlm.nih.gov/pubmed/34417989
http://dx.doi.org/10.1007/s12325-021-01889-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379562/
https://www.ncbi.nlm.nih.gov/pubmed/34417989
http://dx.doi.org/10.1007/s12325-021-01889-2

Ejemplares similares